Market

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through
Read More

Related Posts

Rocket Lab makes ‘bold’ satellite move, but shares slide on weak outlook

Rocket Lab makes ‘bold’ satellite move, but shares slid...

Home-builder ETFs down in 2025 after brutal February as these worries weigh

Home-builder ETFs down in 2025 after brutal February as...

Why Nvidia earnings report is good news for its Big Tech rivals

Why Nvidia earnings report is good news for its Big Tec...

South Korea's pension fund logs record 15% investment return in 2024

South Korea's pension fund logs record 15% investment r...

President Prabowo Inaugurates Pegadaian Gold Bank Service, BRI Group Optimistic in Strengthening the National Economy

President Prabowo Inaugurates Pegadaian Gold Bank Servi...

Csg Systems director Ronald Cooper sells $599,580 in stock

Csg Systems director Ronald Cooper sells $599,580 in stock